The French Competition Authority announced its approval for a pending merger between pharmaceutical giants Actavis and Warner Chilcott, say reports. Actavis’s buyout of Warner Chilcott remains pending. The German Federal Cartel Office has similarly cleared the deal and, according to a press release, the parties have now obtained permission from all ex-US antitrust regulators. Financial details of the deal were not made public. Actavis, based in the US, recently went head-to-head with the US Federal Trade Commission in the Supreme Court; the Court found that so-called pay-for-delay deals, which delay cheaper, generic forms of pharmaceuticals from being sold, can be subject to antitrust lawsuits.
Full Content: RTT News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI